PMEF
DAWN

Point72 Middle East FZE’s Day One Biopharmaceuticals DAWN Stock Holding History

Point72 Middle East FZE’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13,779
Closed -$184K – 1650
2023
Q1 		$184K Buy
+13,779
New +$269K 0.01% 964

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return

Point72 Middle East FZE's DAWN Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Day One Biopharmaceuticals (DAWN) in Q2 2023, closing a stake of 13,779 shares — an estimated $184K sold.

Point72 Middle East FZE first reported a position in DAWN in Q1 2023 and held it in 1 quarter. The position peaked at $184K in Q1 2023. 140 funds tracked by Wall St. Rank hold DAWN as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Day One Biopharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 13,779 Day One Biopharmaceuticals shares in Q2 2023, an estimated $184K.
  • Point72 Middle East FZE first reported a position in Day One Biopharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Day One Biopharmaceuticals position peaked at $184K in Q1 2023.
  • 140 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.